Advertisement

The better outcomes of diffuse large B-cell lymphoma in adolescents and young adults

  • Junnan Wang
  • Fengshang Yan
  • Yiran Wang
Letter to the Editor
  • 10 Downloads

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Suzuki Y, Yano T, Suehiro Y, Iwasaki H, Hidaka M, Otsuka M et al (2018) Clinical characteristics and outcomes of diffuse large B-cell lymphoma in adolescents and young adults. Int J Hematol.  https://doi.org/10.1007/s12185-018-2449-8 Google Scholar
  2. 2.
    Park HS, Lloyd S, Decker RH, Wilson LD, Yu JB. Overview of the Surveillance, Epidemiology, and End Results Database: evolution, data variables, and quality assurance. Curr Probl Cancer. 2012;36(4):183–90.CrossRefPubMedGoogle Scholar
  3. 3.
    Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–42.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Kaya H, Peressini B, Jawed I, Martincic D, Elaimy A, Lamoreaux W, et al. Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. Int J Hematol. 2012;95(1):64–70.CrossRefPubMedGoogle Scholar
  5. 5.
    Coso D, Garciaz S, Esterni B, Broussais-Guillaumot F, Ivanov V, Aurran-Schleinitz T, et al. Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55 patients. Leuk Lymphoma. 2014;55(8):1849–53.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  1. 1.Basic Medical CollegeNavy Medical UniversityShanghaiChina
  2. 2.Department of Oncology, Changhai HospitalNavy Medical UniversityShanghaiChina

Personalised recommendations